ESR1 and breast cancer: The relevance of these long-range chromatin interactions to breast cancer is demonstrated by work showing that aberrant genomic amplification of ER-occupied enhancers can negatively impact on survival and therapy response through the formation of novel rogue long-range target-promoter interactions (54-56).